Advertisement
U.S. markets close in 5 hours 29 minutes
  • S&P 500

    5,250.51
    +2.02 (+0.04%)
     
  • Dow 30

    39,735.60
    -24.48 (-0.06%)
     
  • Nasdaq

    16,390.83
    -8.70 (-0.05%)
     
  • Russell 2000

    2,121.83
    +7.48 (+0.35%)
     
  • Crude Oil

    82.35
    +1.00 (+1.23%)
     
  • Gold

    2,226.10
    +13.40 (+0.61%)
     
  • Silver

    24.75
    -0.01 (-0.03%)
     
  • EUR/USD

    1.0808
    -0.0021 (-0.19%)
     
  • 10-Yr Bond

    4.1980
    +0.0020 (+0.05%)
     
  • GBP/USD

    1.2639
    +0.0001 (+0.01%)
     
  • USD/JPY

    151.2640
    +0.0180 (+0.01%)
     
  • Bitcoin USD

    71,040.70
    +1,342.23 (+1.93%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,962.90
    +30.92 (+0.39%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Enanta Pharmaceuticals announces NIH unit to fund Bicyclolides development

Enanta Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, has agreed to provide additional funding of $9.2M to its existing contract with Enanta to fund preclinical and early clinical development for a new class of bridged bicyclic antibiotics known as Bicyclolides. NIAID is funding development of the Bicyclolides for use as medical countermeasures against multiple biodefense Category A and B bacteria. This brings total funding from NIAID to date to approximately $23.5M As part of a multi-year contract that was awarded in 2011, this funding could total approximately $42.7M if all project milestones are met and NIAID exercises all its options to fund additional development under the contract.

Advertisement